Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 5/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22454909 | 0.97 | CTSS (0.34) | CA2CA1CAPN1CTSSCTSK | |
| SCHEMBL18911532 | 0.90 | GLP1R (0.39) | CA2CA1GLP1R | |
| SCHEMBL18912601 | 0.82 | GLP1R (0.41) | CA2CA1CAPN1CTSSCTSK | |
| SCHEMBL18911933 | 0.80 | GLP1R (0.45) | CA2CA1CAPN1CTSSCTSK | |
| SCHEMBL18911535 | 0.75 | GLP1R (0.42) | CA2CA1CAPN1CTSSCTSK | |
| SCHEMBL22454935 | 0.71 | — | — | |
| SCHEMBL18906906 | 0.70 | GLP1R (0.49) | CA2CA1CAPN1CTSSCTSK | |
| SCHEMBL18906902 | 0.70 | GLP1R (0.49) | CA2CA1CAPN1CTSSCTSK | |
| SCHEMBL23475976 | 0.70 | CTSK (0.44) | CA2CA1CAPN1CTSSCTSK | |
| SCHEMBL16853378 | 0.70 | CTSK (0.44) | CA2CA1CAPN1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | CA2 2471/4885CA1 569/4885CAPN1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.